Vascular dysfunction in patients with chronic arsenosis can be reversed by reduction of arsenic exposure.
Chronic arsenic exposure causes vascular diseases associated with systematic dysfunction of endogenous nitric oxide. Replacement of heavily arsenic-contaminated drinking water with low-arsenic water is a potential intervention strategy for arsenosis, although the reversibility of arsenic intoxication has not established. In the present study, we examined urinary excretion of cyclic guanosine 3 ,5 -monophosphate (cGMP), a second messenger of the vasoactive effects of nitric oxide, and signs and symptoms for peripheral vascular function in 54 arsenosis patients before and after they were supplied with low-arsenic drinking water in an endemic area of chronic arsenic poisoning in Inner Mongolia, China. The arsenosis patients showed a marked decrease in urinary excretion of cGMP (mean +/- SEM: male, 37.0 +/- 6.1; female, 37.2 +/- 5.4 nmol/mmol creatinine), and a 13-month period of consuming low-arsenic drinking water reversed this trend (male, 68.0 +/- 5.6; female, 70.6 +/- 3.0 nmol/mmol creatinine) and improved peripheral vascular response to cold stress. Our intervention study indicates that peripheral vascular disease in arsenosis patients can be reversed by exposure cessation and has important implications for the public health approach to arsenic exposure.
Pi
Jingbo
J
Graduate School of Medical Sciences, University of Tsukuba, Tsukuba, Japan.
Yamauchi
Hiroshi
H
Sun
Guifan
G
Yoshida
Takahiko
T
Aikawa
Hiroyuki
H
Fujimoto
Wataru
W
Iso
Hiroyasu
H
Cui
Renzhe
R
Waalkes
Michael P
MP
Kumagai
Yoshito
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D020261:Arsenic Poisoning / Q000150:complications* / Q000517:prevention & control*; D015415:Biomarkers / Q000032:analysis; D002648:Child; D002681:China; D006152:Cyclic GMP / Q000652:urine; D004781:Environmental Exposure; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D011634:Public Health; D014652:Vascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D018508:Water Purification; D014881:Water Supply
D015415:Biomarkers; D009569:Nitric Oxide; D006152:Cyclic GMP
Free Radic Biol Med. 2000 Apr 1;28(7):1137-42
10832076
Science. 1999 Mar 5;283(5407):1458-9
10206874
Circulation. 2002 Apr 16;105(15):1804-9
11956123
J Dermatol. 2002 Mar;29(3):123-30
11990246
Cardiovasc Res. 2002 Aug 1;55(2):250-60
12123764
Environ Health Perspect. 2003 Apr;111(4):513-7
12676608
Free Radic Biol Med. 2003 Jul 1;35(1):102-13
12826260
Circulation. 2003 Oct 28;108(17):2049-53
14581383
Atherosclerosis. 2004 Jan;172(1):161-6
14709371
Toxicol Appl Pharmacol. 2004 Aug 1;198(3):450-7
15276426
Lancet. 1990 Aug 18;336(8712):442
1974970
Epidemiol Rev. 1994;16(2):184-209
7713176
Circulation. 1997 Apr 15;95(8):2068-74
9133517
Nature. 1998 Sep 24;395(6700):338
9759723
Hypertension. 1999 Jan;33(1):74-8
9931084
Environ Health Perspect. 2002 Apr;110(4):331-6
11940449